Nyxoah S.A.

NasdaqGM:NYXH

Sector

🏥 Health Care

Industries

💻 Telehealth

🧬 Biotechnology

🔬 Clinical Trials

🩺 Medical Instruments

Location

Belgium

Market Cap

USD 290.33 M

Share Price

USD 7.54

Avg Daily Volume

169,742

Change (1 day)

-0.27%

Change (1 year)

-6.10%

Change (YTD)

-5.75%

Nyxoah S.A. Gross Profit Margin for the Trailing 12 Months (TTM) ending December 31, 2024: 52.00%

Nyxoah S.A. Gross Profit Margin is 52.00% for the Trailing 12 Months (TTM) ending December 31, 2024, a 15.57% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Nyxoah S.A. Gross Profit Margin for the Trailing 12 Months (TTM) ending December 31, 2023 was 44.99%, a -28.14% change year over year.
Nyxoah S.A. Gross Profit Margin for the Trailing 12 Months (TTM) ending December 31, 2022 was 62.61%, a -3.10% change year over year.
Nyxoah S.A. Gross Profit Margin for the Trailing 12 Months (TTM) ending December 31, 2021 was 64.61%, a -105.49% change year over year.
Nyxoah S.A. Gross Profit Margin for the Trailing 12 Months (TTM) ending December 31, 2020 was -1,177.65%.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Gross Profit Margin	EBIT Margin	EBITDA Margin	Net Income Margin

NasdaqGM: NYXH

Nyxoah S.A.

CEO	Mr. Olivier Taelman
IPO Date	April 28, 2021
Location	Belgium
Headquarters	Rue Edouard Belin 12
Employees	183
Sector	🏥 Health Care
Industries Telehealth 🧬 Biotechnology 🔬 Clinical Trials 🩺 Medical Instruments

Description

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.